Genomics in practice - a review of inherited cardiac conditions

Abstract

Interest in inherited cardiovascular conditions (ICCs) is fueled by resources devoted to its diagnosis, management, and research. The rapid advancement of DNA genomic sequencing deepens our understanding of ICCs. The ICC genomic landscape empowers the development of diagnostic guidelines and the discovery of potential therapeutic targets and promises novel therapeutics, especially in precision cardiology. Therefore, it is essential for healthcare institutes and systems to develop contextual frameworks based on current guidelines to provide holistic care for patients with ICCs. The clinical frameworks and considerations described in this review provide an overview of the operations of an ICC clinic, including wet and dry lab conditions, work performed by a healthcare professional, and the variety of cases, ranging from cardiomyopathies to arrythmias to aortopathies. Insights from our experience in an ICC clinic in Singapore add to the discussion of the challenges and benefits for patients and clinicians who serve them.

Keywords

Clinical genomics / genetic testing / inherited cardiac condition / cardiomyopathy / arrhythmias / sudden cardiac death

References

[1] BirgerM,RothGA,DielemanJL.Spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996 to 2016.Circulation2021;144:271-82 PMCID:PMC8316421

[2] TownsendN,LucyWright F.Epidemiology of cardiovascular disease in Europe.Nat Rev Cardiol2022;19:133-43

[3] HeatherJM.The sequence of sequencers: the history of sequencing DNA.Genomics2016;107:1-8 PMCID:PMC4727787

[4] SpertusJA,ElliottP.Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2021;397:2467-75

[5] FDA. FDA approves new drug to improve heart function in adults with rare heart condition. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition [Last accessed on 20 Feb 2023]

[6] MusunuruK,DaySM.Genetic testing for inherited cardiovascular diseases: a scientific statement from the american heart association.Circ Genom Precis Med2020;13:e000067

[7] LandstromAP,GelbBD.Genetic testing for heritable cardiovascular diseases in pediatric patients: a scientific statement from the american heart association.Circ Genom Precis Med2021;14:e000086 PMCID:PMC8546375

[8] MaronBJ,DanielsonGK.American college of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American college of cardiology foundation task force on clinical expert consensus documents and the European society of cardiology committee for practice guidelines.J Am Coll Cardiol2003;42:1687-713

[9] WeintraubRG,MacdonaldP.Dilated cardiomyopathy.Lancet2017;390:400-14

[10] HershbergerRE,MoralesA.Dilated cardiomyopathy: the complexity of a diverse genetic architecture.Nat Rev Cardiol2013;10:531-47

[11] McKennaWJ.Epidemiology of the inherited cardiomyopathies.Nat Rev Cardiol2021;18:22-36

[12] CorradoD,JudgeDP.Arrhythmogenic cardiomyopathy.Circ Res2017;121:784-802

[13] ElliottPM,BorgerMA.2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC).Eur Heart J2014;35:2733-79

[14] MaronBJ,HaasTS,MuellerFO.Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006.Circulation2009;119:1085-92

[15] PodridPJ.Epidemiology and stratification of risk for sudden cardiac death.Clin Cardiol2005;28:I3-11

[16] WildeAAM,PostemaPG.Diagnosis, management and therapeutic strategies for congenital long QT syndrome.Heart2022;108:332-8 PMCID:PMC8862104

[17] MaronBJ.Hypertrophic cardiomyopathy.Lancet2013;381:242-55

[18] MazzarottoF,BoschiB.Contemporary insights into the genetics of hypertrophic cardiomyopathy: toward a new era in clinical testing?.J Am Heart Assoc2020;9:e015473 PMCID:PMC7428545

[19] MarianAJ.Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy.Circ Res2017;121:749-70 PMCID:PMC5654557

[20] InglesJ,ThaxtonC.Evaluating the clinical validity of hypertrophic cardiomyopathy genes.Circ Genom Precis Med2019;12:e002460 PMCID:PMC6410971

[21] KonnoT,SeidmanJG.Genetics of hypertrophic cardiomyopathy.Curr Opin Cardiol2010;25:205-9 PMCID:PMC2932754

[22] WatkinsH,ThierfelderL.Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy.N Engl J Med1995;332:1058-64

[23] NiimuraH,SangwatanarojS.Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.N Engl J Med1998;338:1248-57

[24] KoC,ConcannonM.Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup.Genet Med2018;20:69-75

[25] AradM,GorhamJM.Glycogen storage diseases presenting as hypertrophic cardiomyopathy.N Engl J Med2005;352:362-72

[26] MaronBJ,NishimuraRA.Management of Hypertrophic Cardiomyopathy: JACC state-of-the-art review.J Am Coll Cardiol2022;79:390-414

[27] MaronBJ,MaronMS.Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator.Heart Rhythm2021;18:1012-23

[28] SchultheissHP,CaforioALP.Dilated cardiomyopathy.Nat Rev Dis Primers2019;5:32

[29] MaronBJ,ThieneG.Contemporary definitions and classification of the cardiomyopathies: an American heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention.Circulation2006;113:1807-16

[30] NugentAW,ChondrosP.The epidemiology of childhood cardiomyopathy in Australia.N Engl J Med2003;348:1639-46

[31] TowbinJA,ColanSD.Incidence, causes, and outcomes of dilated cardiomyopathy in children.JAMA2006;296:1867-76

[32] PintoYM,ArbustiniE.Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases.Eur Heart J2016;37:1850-8

[33] MoralesA.Genetic evaluation of dilated cardiomyopathy.Curr Cardiol Rep2013;15:375

[34] vanSpaendonck-Zwarts KY,vanden Berg MP.Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years’ experience.Eur J Heart Fail2013;15:628-36

[35] AckermanMJ,WillemsS.HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).Heart Rhythm2011;8:1308-39

[36] HaasJ,PeilB.Atlas of the clinical genetics of human dilated cardiomyopathy.Eur Heart J2015;36:1123-35a

[37] Escobar-LopezL,MirelisJG.Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy.J Am Coll Cardiol2021;78:1682-99

[38] GigliM,GrawSL.Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy.J Am Coll Cardiol2019;74:1480-90 PMCID:PMC6750731

[39] vanden Hoogenhof MMG,AminAS.RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy related to disturbed calcium handling.Circulation2018;138:1330-42

[40] KayvanpourE,AmrA.Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals.Clin Res Cardiol2017;106:127-39

[41] HasselbergNE,SaberniakJ.Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.Eur Heart J2018;39:853-60 PMCID:PMC5939624

[42] Ortiz-GengaMF,DalFerro M.Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies.J Am Coll Cardiol2016;68:2440-51

[43] HelmsAS,DaySM.Translation of new and emerging therapies for genetic cardiomyopathies.JACC Basic Transl Sci2022;7:70-83 PMCID:PMC8807730

[44] VerdonschotJAJ,WareJS,HeymansSRB.Role of targeted therapy in dilated cardiomyopathy: the challenging road toward a personalized approach.J Am Heart Assoc2019;8:e012514 PMCID:PMC6585365

[45] BosmanLP,JamesCA.Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis.Heart Rhythm2018;15:1097-107

[46] MarcusFI,SherrillD.Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria.Eur Heart J2010;31:806-14

[47] vanLint FHM,TichnellC.Arrhythmogenic right ventricular cardiomyopathy-associated desmosomal variants are rarely de novo.Circ Genom Precis Med2019;12:e002467

[48] TowbinJA,AbramsDJ.2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.Heart Rhythm2019;16:e301-72

[49] JamesCA,vanTintelen JP.The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy.Eur Heart J2020;41:1393-400

[50] BhonsaleA,JamesCA.Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers.Eur Heart J2015;36:847-55

[51] EngberdingR.[Echocardiographic detection of persistent myocardial sinusoids].Z Kardiol1984;73:786-8

[52] MurphyRT,BlanesJG.Natural history and familial characteristics of isolated left ventricular non-compaction.Eur Heart J2005;26:187-92

[53] RossSB,BlanchB.A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults.Eur Heart J2020;41:1428-36

[54] BennettCE.The current approach to diagnosis and management of left ventricular noncompaction cardiomyopathy: review of the literature.Cardiol Res Pract2016;2016:5172308 PMCID:PMC4737020

[55] IchidaF,MiyawakiT.Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background.J Am Coll Cardiol1999;34:233-40

[56] Sedaghat-HamedaniF,ZhuF.Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy.Eur Heart J2017;38:3449-60

[57] IchidaF,BowlesKR.Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome.Circulation2001;103:1256-63

[58] ProbstS,SchulerP.Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype.Circ Cardiovasc Genet2011;4:367-74

[59] HastingsR,HooperC.Combination of whole genome sequencing, linkage, and functional studies implicates a missense mutation in titin as a cause of autosomal dominant cardiomyopathy with features of left ventricular noncompaction.Circ Cardiovasc Genet2016;9:426-35

[60] WangC,HironoK.A wide and specific spectrum of genetic variants and genotype-phenotype correlations revealed by next-generation sequencing in patients with left ventricular noncompaction.J Am Heart Assoc2017;6 PMCID:PMC5634278

[61] LiS,LiuN.Genotype-positive status is associated with poor prognoses in patients with left ventricular noncompaction cardiomyopathy.J Am Heart Assoc2018;7:e009910 PMCID:PMC6474962

[62] StöllbergerC,DobiasC,WegnerC.Frequency of stroke and embolism in left ventricular hypertrabeculation/noncompaction.Am J Cardiol2011;108:1021-3

[63] CaliskanK,TheunsDA.Indications and outcome of implantable cardioverter-defibrillators for primary and secondary prophylaxis in patients with noncompaction cardiomyopathy.J Cardiovasc Electrophysiol2011;22:898-904

[64] SekijimaY. Hereditary transthyretin amyloidosis. In: Adam MP, Everman DB, Mirzaa GM, et al, editors. Seattle: University of Washington, 1993.

[65] MaurerMS,DamyT.Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis.Circ Heart Fail2019;12:e006075 PMCID:PMC6736650

[66] KittlesonMM,AmbardekarAV.Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the american heart association.Circulation2020;142:e7-e22

[67] MaurerMS,GundapaneniB.Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med2018;379:1007-16

[68] BensonMD.Liver transplantation and transthyretin amyloidosis.Muscle Nerve2013;47:157-62

[69] DamyT,SuhrOB.Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).Eur Heart J2019;43:391-400 PMCID:PMC8825236

[70] BrugadaP.Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. a multicenter report.J Am Coll Cardiol1992;20:1391-6

[71] BrugadaJ,ArbeloE,BrugadaR.Present status of brugada syndrome: JACC state-of-the-art review.J Am Coll Cardiol2018;72:1046-59

[72] SieiraJ.The definition of the brugada syndrome.Eur Heart J2017;38:3029-34

[73] ChenQ,ZhangD.Genetic basis and molecular mechanism for idiopathic ventricular fibrillation.Nature1998;392:293-6

[74] MonaskyMM,LocatiET.Evaluating the use of genetics in brugada syndrome risk stratification.Front Cardiovasc Med2021;8:652027 PMCID:PMC8096997

[75] RehmHL,BrooksLD.ClinGen-the clinical genome resource.N Engl J Med2015;372:2235-42 PMCID:PMC4474187

[76] NademaneeK,ChandanamatthaP.Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium.Circulation2011;123:1270-9

[77] LieveKV.Inherited ion channel diseases: a brief review.Europace2015;17 Suppl 2:ii1-6

[78] WatanabeH.Genetics of Brugada syndrome.J Hum Genet2016;61:57-60

[79] CiconteG,SantinelliV.Brugada syndrome genetics is associated with phenotype severity.Eur Heart J2021;42:1082-90 PMCID:PMC7955973

[80] MakarawateP,KhongphatthanayothinA.Common and rare susceptibility genetic variants predisposing to Brugada syndrome in Thailand.Heart Rhythm2020;17:2145-53

[81] YangY,SacherF.Meta-analysis of risk stratification of SCN5A with brugada syndrome: is SCN5A always a marker of low risk?.Front Physiol2019;10:103 PMCID:PMC6389868

[82] PrioriSG,MazzantiA.2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the european society of cardiology (ESC). endorsed by: association for european paediatric and congenital cardiology (AEPC).Eur Heart J2015;36:2793-867

[83] OldeNordkamp LR,KnopsRE.Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications.Heart Rhythm2016;13:443-54

[84] SieiraJ,BrugadaP.Pathogenesis and management of Brugada syndrome.Nat Rev Cardiol2016;13:744-56

[85] SchwartzPJ,InsoliaR.Long-QT syndrome: from genetics to management.Circ Arrhythm Electrophysiol2012;5:868-77 PMCID:PMC3461497

[86] SchwartzPJ.Idiopathic long QT syndrome: progress and questions.Am Heart J1985;109:399-411

[87] PrioriSG,HorieM.HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.Heart Rhythm2013;10:1932-63

[88] HamoshA,AmbergerJS,McKusickVA.Online mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders.Nucleic Acids Res2005;33:D514-7 PMCID:PMC539987

[89] KapplingerJD,SalisburyBA.Spectrum and prevalence of mutations from the first 2500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.Heart Rhythm2009;6:1297-303

[90] CrottiL,SchwartzPJ.The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification.Circulation2007;116:2366-75

[91] MazzantiA,FaragliA.Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long qt syndrome type 3.J Am Coll Cardiol2016;67:1053-8 PMCID:PMC4773513

[92] LeenhardtA,GuicheneyP.Catecholaminergic polymorphic ventricular tachycardia.Circ Arrhythm Electrophysiol2012;5:1044-52

[93] LeenhardtA,DenjoyI,NgocDD.Catecholaminergic polymorphic ventricular tachycardia in children. a 7-year follow-up of 21 patients.Circulation1995;91:1512-9

[94] der Werf C, van Langen IM, Wilde AA. Sudden death in the young: what do we know about it and how to prevent?.Circ Arrhythm Electrophysiol2010;3:96-104

[95] SongJ,JiangY.Advances in the molecular genetics of catecholaminergic polymorphic ventricular tachycardia.Front Pharmacol2021;12:718208 PMCID:PMC8415552

[96] HayashiM,ExtramianaF.Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.Circulation2009;119:2426-34

[97] DeanJC.Marfan syndrome: clinical diagnosis and management.Eur J Hum Genet2007;15:724-33

[98] LoeysBL,BravermanAC.The revised Ghent nosology for the Marfan syndrome.J Med Genet2010;47:476-85

[99] MilewiczDM,DeBacker J.Marfan syndrome.Nat Rev Dis Primers2021;7:64

[100] KeaneMG.Medical management of Marfan syndrome.Circulation2008;117:2802-13

[101] FrankelWC,SpiegelmanA,LeMaireSA.Patients at risk for aortic rupture often exposed to fluoroquinolones during hospitalization.Antimicrob Agents Chemother2019;63 PMCID:PMC6355567

[102] CoelhoSG.Marfan syndrome revisited: from genetics to the clinic.Rev Port Cardiol2020;39:215-26

[103] SakaiLY,RenardM.FBN1: the disease-causing gene for Marfan syndrome and other genetic disorders.Gene2016;591:279-91 PMCID:PMC6639799

[104] GaoLG,HuiRT.Recent molecular biological progress in Marfan syndrome and Marfan-associated disorders.Ageing Res Rev2010;9:363-8

[105] CecchiA,MartinezHR.Missense mutations in FBN1 exons 41 and 42 cause Weill-Marchesani syndrome with thoracic aortic disease and Marfan syndrome.Am J Med Genet A2013;161A:2305-10 PMCID:PMC3829633

[106] EmanuelR,MarcomichelakisJ.Formes frustes of Marfan’s syndrome presenting with severe aortic regurgitation. clinicogenetic study of 18 families.Br Heart J1977;39:190-7 PMCID:PMC483215

[107] McKennaA,BanksE.The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.Genome Res2010;20:1297-303 PMCID:PMC2928508

[108] McLarenW,HuntSE.The ensembl variant effect predictor.Genome Biol2016;17:122

[109] CingolaniP,Wangle L.A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3.Fly2012;6:80-92 PMCID:PMC3679285

[110] WhiffinN,WalshR.Using high-resolution variant frequencies to empower clinical genome interpretation.Genet Med2017;19:1151-8 PMCID:PMC5563454

[111] WuD,ChaiX.Large-scale whole-genome sequencing of three diverse asian populations in singapore.Cell2019;179:736-749.e15

[112] RichardsS,BaleS.Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology.Genet Med2015;17:405-24 PMCID:PMC4544753

[113] MartinAR,FoulgerRE.PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels.Nat Genet2019;51:1560-5

[114] TomarS,ChenCK.Causative variants for inherited cardiac conditions in a southeast asian population cohort.Circ Genom Precis Med2022;15:e003536

[115] AdzhubeiI,SunyaevSR.Predicting functional effect of human missense mutations using PolyPhen-2.Curr Protoc Hum Genet2013;7:7.20 PMCID:PMC4480630

[116] SimNL,HuJ,SchneiderG.SIFT web server: predicting effects of amino acid substitutions on proteins.Nucleic Acids Res2012;40:W452-7 PMCID:PMC3394338

[117] ChunS.Identification of deleterious mutations within three human genomes.Genome Res2009;19:1553-61 PMCID:PMC2752137

[118] SchwarzJM,SchuelkeM.MutationTaster evaluates disease-causing potential of sequence alterations.Nat Methods2010;7:575-6

[119] ShihabHA,CooperDN.Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models.Hum Mutat2013;34:57-65 PMCID:PMC3558800

[120] PollardKS,RosenbloomKR.Detection of nonneutral substitution rates on mammalian phylogenies.Genome Res2010;20:110-21 PMCID:PMC2798823

[121] RentzschP,CooperGM,KircherM.CADD: predicting the deleteriousness of variants throughout the human genome.Nucleic Acids Res2019;47:D886-94 PMCID:PMC6323892

[122] QuangD,XieX.DANN: a deep learning approach for annotating the pathogenicity of genetic variants.Bioinformatics2015;31:761-3 PMCID:PMC4341060

[123] LandrumMJ,RileyGR.ClinVar: public archive of relationships among sequence variation and human phenotype.Nucleic Acids Res2014;42:D980-5 PMCID:PMC3965032

[124] SunY,HofferMJ.Next-generation diagnostics: gene panel, exome, or whole genome?.Hum Mutat2015;36:648-55

[125] CirinoAL,McDonoughB.A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients.Circ Cardiovasc Genet2017;10 PMCID:PMC5683423

[126] MeienbergJ,OexleK.Clinical sequencing: is WGS the better WES?.Hum Genet2016;135:359-62 PMCID:PMC4757617

[127] PuaCJ,MiaoK.Development of a Comprehensive sequencing assay for inherited cardiac condition genes.J Cardiovasc Transl Res2016;9:3-11

[128] SturmAC.Cardiovascular cascade genetic testing: exploring the role of direct contact and technology.Front Cardiovasc Med2016;3:11 PMCID:PMC4835441

[129] NhereraL,MinhasR,HumphriesSE.Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.Heart2011;97:1175-81

[130] KamS,ForrestL,FooR.Experience of Asian males communicating cardiac genetic risk within the family.J Community Genet2018;9:293-303 PMCID:PMC6002304

[131] McGuireAL.Informed consent in genomics and genetic research.Annu Rev Genomics Hum Genet2010;11:361-81 PMCID:PMC3216676

[132] BorryP,SprumontD.Legislation on direct-to-consumer genetic testing in seven European countries.Eur J Hum Genet2012;20:715-21 PMCID:PMC3376265

[133] MillerDT,ChungWK.ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).Genet Med2021;23:1381-90

[134] MaronBJ,SemsarianC.Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy.Am J Cardiol2011;107:604-8

[135] SafarovaMS,KulloIJ.A call for training programmes in cardiovascular genomics.Nat Rev Cardiol2021;18:539-40

[136] AhmadF,AckermanMJ.Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the american heart association.Circ Genom Precis Med2019;12:e000054

[137] deVries J,DoumboO.Ethical issues in human genomics research in developing countries.BMC Med Ethics2011;12:5 PMCID:PMC3076260

[138] GirolamiF,BenelliM.Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications.J Cardiovasc Med2018;19:1-11 PMCID:PMC5732648

[139] HamvasA,NogeeLM.Informed consent for genetic research.Arch Pediatr Adolesc Med2004;158:551-5

[140] MOH. Updates to code of practice on the standards for the provision of clinical genetic/genomic testing services and clinical laboratory genetic/genomic testing services. 2020. Available from: https://www.moh.gov.sg/docs/librariesprovider5/licensing-terms-and-conditions/moh-cir-no-234_2020_16dec20_genetic-testing.pdf [Last accessed on 20 Feb 2023]

[141] MathaiyanJ,DavisS.Ethics of genomic research.Perspect Clin Res2013;4:100-4 PMCID:PMC3601693

[142] WanZ,ClaytonEW,KantarciogluM.Sociotechnical safeguards for genomic data privacy.Nat Rev Genet2022;23:429-45

[143] GodardB,PembreyM,FarndonP.Genetic information and testing in insurance and employment: technical, social and ethical issues.Eur J Hum Genet2003;11 Suppl 2:S123-42

[144] MOH. Moratorium on genetic testing and insurance ministry of health, Singapore. 2021. Available from: https://www.moh.gov.sg/resources-statistics/moratorium-on-genetic-testing-and-insurance [Last accessed on 20 Feb 2023]

[145] LiMX.Structure and function of cardiac troponin C (TNNC1): implications for heart failure, cardiomyopathies, and troponin modulating drugs.Gene2015;571:153-66 PMCID:PMC4567495

[146] LetsasKP,BazoukisG.A novel variant of RyR2 gene in a family misdiagnosed as congenital long QT syndrome: The importance of genetic testing.J Electrocardiol2020;60:8-11

[147] KryshtalDO,EglyCL.RYR2 channel inhibition is the principal mechanism of flecainide action in CPVT.Circ Res2021;128:321-31 PMCID:PMC7864884

[148] PrioriSG,SchwartzPJ.Low penetrance in the long-QT syndrome: clinical impact.Circulation1999;99:529-33

[149] TesterDJ,WillML.Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing.Heart Rhythm2005;2:1099-105

[150] Medeiros-DomingoA,TesterDJ.The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis.J Am Coll Cardiol2009;54:2065-74 PMCID:PMC2880864

[151] SchrijverI,OdomR.Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes.Am J Hum Genet2002;71:223-37 PMCID:PMC379156

[152] YouilR,BullE.Enzymatic mutation detection (EMD) of novel mutations (R565X and R1523X) in the FBN1 gene of patients with Marfan syndrome using T4 endonuclease VII.Hum Mutat2000;16:92-3

[153] SöylenB,AbuzaininA.Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations.Clin Genet2009;75:265-70

[154] BaudhuinLM,LagerstedtSA.Increased frequency of FBN1 truncating and splicing variants in Marfan syndrome patients with aortic events.Genet Med2015;17:177-87